Vijay Dharmarpu

Project Fellow (UGC-DAE)

Phone:

+91 9618324978

Email:

msldnrc@gmail.com

Address:

Molecular Spectroscopy Laboratory,

Dept. of Physics, D.N.R. College (A),

Bhimavaram, West Godavari (Dist.)

Andhra Pradesh, India 534 202.

Area of Intrest (Research)

Atomic and Molecular Physics, DFT and First principle methods

Synchrotron based spectroscopic studies

Vijay Dharmarpu is an active Indian researcher and scholar in Atomic, Molecular and Computational Physics primarily known for his work in molecular spectroscopy and computational drug discovery workflows.

Research Experience

01 September 2017 - 31 March 2023

15 Aug 2015 - May 2017

UGC-DAE Project Fellow

Project Title: "Spectroscopic investigation of Benzofuran and coumarin derivatives of biological importance using theoretical and experimental techniques"

MOLECULAR SPECTROSCOPY LABORATORY,

Department Of Physics, D.N.R. COLLEGE (Autonomous), BHIMAVARAM, ANDHRA PRADESH, INDIA-534202.

Sponsored by UGC-DAE-IUC Indore, Government of India., Project Code : CSR-IC-BL-56/CRS-173/2016-17/837

Project Fellow

Title of Project "Structural, Optical And Photoluminescence Studies On Eu -Doped Mgo Nanoparticles: Synthesized By Polyol Method"

CRYSTAL GROWTH NANO SCIENCE RESEARCH CENTER,

Department Of Physics, GOVERNMENT COLLEGE (Autonomous), RAJAHMUNDRY, ANDHRA PRADESH, INDIA-533105.

*A Part of Major Research Project, BRNS -BARC Chemistry Division, MUMBAI

25-MAY-2015 to 18-JULY-2015

Project Trainee

Advanced Orientation Course On Accelerators, Lasers & Related Science And Technologies (OCAL -2015)

RAJA RAMANNA CENTRE FOR ADVANCED TECHNOLOGY (RRCAT), INDORE, MADHYA PRADESH, INDIA – 45201.

About Me

Vijay Dharmarpu is an active Indian researcher and scholar in Atomic, Molecular, and Computational Physics, primarily known for his work in molecular spectroscopy and computational drug discovery workflows.

He operates out of the Molecular Spectroscopy Laboratory in the Department of Physics at D.N.R. College (Autonomous) in Bhimavaram, Andhra Pradesh, India, and is affiliated with Adikavi Nannaya University.

ResearchGate

His research bridges the gap between physics-based material characterization and biochemistry through a few core areas:

Spectroscopic Studies: He specializes in experimental and theoretical analysis of organic and heterocyclic compounds (such as benzofurans, benzonitrile, and coumarins). He frequently utilizes techniques like Fourier-transform infrared (FT-IR) spectroscopy, FT-Raman, and UV-Vis methods to map molecular structures.

ResearchGate

Computational Simulations (DFT): He extensively applies Density Functional Theory (DFT) to model quantum mechanical properties, optimize molecular geometry, map electronic structures, and analyze frontier molecular orbitals (HOMO-LUMO densities).

In Silico Drug Discovery & Molecular Docking: A significant portion of his collaborative work involves virtual screening, molecular docking simulations, and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiling to predict the biological activity of natural compounds against various therapeutic targets.

Key Collaborative Research & Publications

Dharmarpu works heavily within international collaborative research networks, contributing physics and computational modeling expertise to biomedical and pharmacological studies. Some notable peer-reviewed work includes:

Astrochemical Spectroscopy (2022): Collaborated with researchers from the Bhabha Atomic Research Centre (BARC) on a detailed spectroscopic study of benzonitrile using the synchrotron light source Indus-1, a study heavily cited in astrochemical and interstellar matter research.

ResearchGate

Influenza H3N2 Inhibitors (2025/2026): Contributed to structure-guided virtual screening and molecular docking to identify novel epicatechin derivatives as potential inhibitors of the influenza virus H3N2 nucleoprotein.

Google Scholar

Diabetes Therapeutics (2024): Co-authored research providing experimental and computational insights into using compounds from Gongronema latifolium leaves as GLP-1 receptor agonists for managing diabetes.

Get Me